✦ LIBER ✦

Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

✍ Scribed by Kris, M.G; Herbst, R; Rischin, D; LoRusso, P; Baselga, J; Hammond, L; Feyereislova, A; Ochs, J; Averbuch, S

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pilot trial of ZD1839 (IressaTM), an ora

✍ Laurie, S.A; Miller, V.A; Johnson, D; Ng, K.K; Heelan, R.T; Pizzo, B.A; Perez, W 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 116 KB

ZD1839, a novel, oral epidermal growth f

✍ Pallis, A.G.; Mavroudis, D.; Androulakis, N.; Souglakos, J.; Kouroussis, C.; Boz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 195 KB

Antitumor activity of the epidermal grow

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 132 KB

O-195 Activating mutations (muts) in the

✍ Taron, M.; Santarpia, C.; Ichinose, Y.; Mok, T.; Massuti, B.; Queralt, C.; Sanch 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 156 KB

A phase I and pharmacokinetic study of d

✍ Glenwood Goss; Frances A. Shepherd; Scott Laurie; Isabelle Gauthier; N. Leighl; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 137 KB